RCT of 482 patients with symptomatic femoropopliteal disease: sirolimus- vs paclitaxel-coated balloons met non-inferiority for 12-month primary patency (73.9% vs 74.9%), though not robust in sensitivity analyses, and for the clinical composite (90.5% vs 92.7%).
RCTn = 482
Teichgräber et al. Comparison of Sirolimus- vs Paclitaxel-Coated Balloon Angioplasty for Femoropopliteal Artery Disease: The SIRONA Randomized Noninferiority Trial